Nigeria Centre for Disease Control
© Credits

Mpox

    Overview

    Mpox (previously known as monkeypox) is a viral disease caused by an orthopoxvirus called monkeypox virus. It spreads mainly through close contact with someone who has mpox, causing a painful rash, enlarged lymph nodes and fever. It can make people very sick and leave scars.

    The disease mainly spreads from person to person through close contact. This includes, but isn’t limited to, sexual contact. Transmission occurs through exposure to bodily fluids; lesions on the skin or on internal mucosal surfaces, such as in the mouth or throat; respiratory particles; and contaminated objects. 

    In areas where animals carry the virus, mpox is a zoonotic disease, meaning it can spread from animals to humans. It's found in tropical rainforests in central, east and west Africa, where small mammals such as squirrels, Gambian pouched rats, dormice, and various species of monkeys may be carriers.

    Since May 2022, mpox has spread globally, with cases reported from countries without previously documented mpox transmission. The spread in most countries today is from people and not animals.

    Symptoms

    Mpox typically causes a fever, a rash resembling pimples or blisters and swollen lymph nodes.   Symptoms usually appear within a week of exposure but can take anywhere from 1 to 21 days to develop.

    The illness often begins with a feverish phase lasting 1 to 3 days with symptoms including intense headache, swollen lymph nodes back pain, muscle aches and severe fatigue. The first stage is followed by the skin eruption stage, lasting from 2 to 4 weeks. Lesions evolve from macules (lesions with a flat base) to papules (raised firm painful lesions) to vesicles (filled with clear fluid) to pustules (filled with pus), followed by scabs or crusts.  They can leave scars. For some people, the first symptom of mpox is the rash.

    Some people with mpox become very sick and it can even be fatal in some cases. Children, pregnant people and people with weak immune systems, including people living with HIV that is not well controlled, are at higher risk for serious illness and death due to complications from mpox.

    Prevention and treatment

    Prevention and control of mpox rely on raising awareness in communities and educating health workers to prevent infection and stop transmission.

    Mpox vaccines also provide protection against infection and severe disease. WHO recommends the use of vaccines for those most at risk of exposure during outbreaks, including people who have had close contact with someone with mpox, and health workers. People who were vaccinated against smallpox in childhood may have some cross-protection against mpox. 

    To prevent spread, close contact with people who have mpox or with contaminated materials should be avoided. Masks, gloves and other personal protective equipment should be worn while taking care of the sick, whether in a health facility or at home. 

    Where animal-to-human transmission is possible, contact with sick or dead animals should be avoided, and all foods containing animal meat or parts must be properly cooked before consumption. 

    Care of patients with mpox should focus on managing symptoms to make people feel better, and to prevent medical complications. Potential treatments against mpox are being developed and tested.

    News

    All →

    Latest publications

    All →
    Community protection for the mpox response: a comprehensive set of actions

    This is the first of a collection of technical briefs devoted to community protection for mpox. These briefs provide practical information for strengthening...

    Surveillance, case investigation and contact tracing for mpox: interim guidance, 27 November 2024

    This is an updated version of the interim guidance for surveillance, case investigation and contact-tracing for mpox published on 20 May 2024. It applies...

    Safety monitoring of mpox vaccines using cohort event monitoring: a WHO protocol

    On the front page also: Protocol identifying number: ERC.0004184. Use of this protocol: As a master protocol to be approved by WHO Ethical Review Committee...

    Considerations for border health and points of entry for mpox: interim guidance

    On 14 August 2024, the Director-General of the World Health Organization determined that the upsurge of mpox in a growing number of countries in Africa...

    WHO documents

    All →
    Risk evaluation of clade Ib monkeypox virus: Review of evidence as of 10 December 2024

    This document summarizes the current evidence regarding clade Ib monkeypox virus (MPXV), identifies gapsin understanding, recommends studies to address...

    Risk evaluation of clade Ia monkeypox virus: Review of evidence as of 10 December 2024

    This document summarizes the current evidence regarding clade Ia monkeypox virus (MPXV), identifies gapsin understanding, recommends studies to address...

    This Mpox Global SPRP Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress...

    Thumbnail for Situational Report Mpox 45

    This is the 45th situation report for the multi-country outbreak of mpox, which provides details on the latest epidemiological trends. The outbreak of...